Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Experimental Eye Research

• Publication date

  2011-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.exer.2011.02.015PMID 21376717
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• INO-8875, an Adenosine A1 Agonist, Lowers Intraocular Pressure Through the Conventional Outflow Pathway

  2010influential reference
• Dose-Escalating, Double-Masked, Vehicle-Controlled Trial of the IOP-Reducing Effect of the EP2 Agonist PF-04217329

  2010influential reference
• Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.

  2009cited by this paper
• Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers.

  2008influential reference
• The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey.

  2006cited by this paper
• Stimulation of cannabinoid (CB1) and prostanoid (EP2) receptors opens BKCa channels and relaxes ocular trabecular meshwork.

  2005cited by this paper
• Prostaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogen-activated protein kinases.

  2005cited by this paper
• Immunolocalization of prostanoid EP receptor isotypes in human trabecular meshwork

  2004cited by this paper
• Comparison of Prostaglandin F2α, Bimatoprost (Prostamide), and Butaprost (EP2 Agonist) on Cyr61 and Connective Tissue Growth Factor Gene Expression*

  2003cited by this paper
• EP2 and EP4 prostanoid receptor signaling.

  2003cited by this paper
• Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide.

  2003cited by this paper
• Cloning and expression of the rabbit prostaglandin EP2 receptor

  2002cited by this paper
• Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues.

  2002cited by this paper
• Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 *

  2002cited by this paper
• Prostanoid receptors: subtypes and signaling.

  2001influential reference
• Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment.

  2001cited by this paper
• Prostanoid receptor gene expression profile in human trabecular meshwork: a quantitative real-time PCR approach.

  2001cited by this paper
• The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators.

  2000cited by this paper
• Aqueous Humor Dynamics in Monkeys with Laser-Induced Glaucoma

  2000cited by this paper
• The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration

  2000cited by this paper
• Molecular cloning and characterization of the canine prostaglandin E receptor EP2 subtype.

  1999cited by this paper
• Comparative glaucomatology. I: The spontaneous glaucomas.

  1998cited by this paper
• Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle.

  1997cited by this paper
• Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells.

  1997cited by this paper
• Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells.

  1996cited by this paper
• Molecular Characterization and Ocular Hypotensive Properties of the Prostanoid EP2 Receptor

  1995influential reference

• Ligand-based machine learning models to classify active compounds for prostaglandin EP2 receptor

  2026cites this paper
• The Clinical Efficacy of a Topical Selective EP2 Receptor Agonist Against Feline Glaucoma That Is Not Responsive to Conventional Anti-Glaucoma Eyedrops.

  2025cites this paper
• Modulating inflammatory prostaglandin E2 signaling to mitigate neurobehavioral comorbidities associated with seizure disorders

  2025cites this paper
• Prostanoid receptors in GtoPdb v.2025.3

  2025cites this paper
• Prostaglandin Analogs and Eupatilin as Treatments for Nephronophthisis

  2025cites this paper
• Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

  2024cites this paper
• Taprenepag restores maternal–fetal interface homeostasis for the treatment of neurodevelopmental disorders

  2024influential citation
• Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.

  2024cites this paper
• FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.

  2023cites this paper
• Short-Term Efficacy and Long-Term Tolerability of Omidenepag Isopropyl 0.002% Ophthalmic Solution in Korean Glaucoma Patients

  2023cites this paper
• Pharmacological cAMP stimulation via prostaglandin receptors rescues ciliary defects in CEP290-deficient human and mouse models

  2023cites this paper
• Identifying G protein-coupled receptors involved in adipose tissue function using the innovative RNA-seq database FATTLAS

  2023cites this paper
• Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients

  2023cites this paper
• The discovery of cyclic γ-AApeptides as the promising ligands targeting EP2.

  2023cites this paper
• Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment.

  2023cites this paper
• The Roles Played by FP/EP3 Receptors During Pressure-lowering in Mouse Eyes Mediated by a Dual FP/EP3 Receptor Agonist

  2022cites this paper
• Role of Prostaglandins in Nitric Oxide-Induced Glial Cell-Mediated Vasodilation in Rat Retina

  2022cites this paper
• Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension

  2022cites this paper
• Eicosanoid Pathway Modulators: Prostaglandins, Prostacyclin, and Thromboxane

  2021cites this paper
• The EP2 agonist, omidenepag, alters the physical stiffness of 3D spheroids prepared from human corneal stroma fibroblasts differently depending on the osmotic pressure

  2021cites this paper
• Prostanoid receptors in GtoPdb v.2021.2

  2021cites this paper
• Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases

  2020cites this paper
• Prostaglandin E2 receptors and their role in gastrointestinal motility - potential therapeutic targets.

  2020cites this paper
• The role of EP2 receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1

  2020cites this paper
• Systemic Drug Delivery to the Posterior Segment of the Eye: Overcoming Blood–Retinal Barrier Through Smart Drug Design and Nanotechnology

  2020cites this paper
• Recent Developments for the Treatment of Glaucoma

  2020cites this paper
• Understanding metabolism related differences in ocular efficacy of MGV354

  2020cites this paper
• Druggable Prostanoid Pathway.

  2020cites this paper
• Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells

  2020cites this paper
• A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method

  2019cites this paper
• Prostanoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma

  2019cites this paper
• The affinity, intrinsic activity and selectivity of a structurally novel EP2 receptor agonist at human prostanoid receptors

  2019cites this paper
• Altered PGE2-EP2 is associated with an excessive immune response in HBV-related acute-on-chronic liver failure

  2019cites this paper
• Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys

  2018cites this paper
• Selectively targeting prostanoid E (EP) receptor-mediated cell signalling pathways: Implications for lung health and disease.

  2018cites this paper
• Signal crosstalk between calcium-sensing and prostanoid receptors and its role in parathyroid hormone secretion

  2018cites this paper
• Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma

  2018cites this paper
• Glaucoma Pharmacologic Characterization of Omidenepag Isopropyl , a Novel Selective EP 2 Receptor Agonist , as an Ocular Hypotensive Agent

  2018cites this paper
• Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.

  2018cites this paper
• A Combined Clinical and Langmuir Film Study of Natural Tear Films

  2017cites this paper
• Ocular non-P450 oxidative, reductive, hydrolytic, and conjugative drug metabolizing enzymes

  2017cites this paper
• Structural features of subtype-selective EP receptor modulators.

  2017cites this paper
• Ocular Hypertension and Glaucoma: A Review and Current Perspectives

  2017cites this paper
• Prostaglandin EP2 receptor signaling protects human trabecular meshwork cells from apoptosis induced by ER stress through down-regulation of p53.

  2016cites this paper
• Activation of Prostaglandin FP and EP2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells.

  2016cites this paper
• Prostaglandin analogues: current treatment option for glaucoma

  2016cites this paper
• Discovery of G Protein-Biased EP2 Receptor Agonists.

  2016cites this paper
• Latanoprostene Bunod, a Dual-acting Nitric Oxide Donating Prostaglandin Analog for Lowering of Intraocular Pressure

  2016cites this paper
• Controversies in Glaucoma: Current Medical Treatment and Drug Development.

  2015cites this paper
• Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2

  2015cites this paper
• Aqueous humor outflow: dynamics and disease.

  2015cites this paper
• Effect of AR-13324 on Episcleral Venous Pressure in Dutch Belted Rabbits

  2015cites this paper
• 78 Glaucoma EUROPEAN OPHTHALMIC REVIEW The European Glaucoma Society Guidelines – Evidence , Consensus and Updates

  2014cites this paper
• Exciting directions in glaucoma.

  2014cites this paper
• Development of second generation EP2 antagonists with high selectivity.

  2014cites this paper
• Investigation of Ocular Events Associated with Taprenepag Isopropyl, a Topical EP2 Agonist in Development for Treatment of Glaucoma

  2014cites this paper
• Prostanoid receptor EP2 as a therapeutic target.

  2014cites this paper
• Novel Strategies for Anterior Segment Ocular Drug Delivery

  2013cites this paper
• Study Design and Methodologies for Evaluation of Anti-glaucoma Drugs

  2013cites this paper
• Subclinical Increased Anterior Stromal Reflectivity With Topical Taprenepag Isopropyl

  2013cites this paper
• The 2-Series Eicosanoids in Cancer: Future Targets for Glioma Therapy?

  2013cites this paper
• An effective prodrug strategy to selectively enhance ocular exposure of a cannabinoid receptor (CB1/2) agonist.

  2013cites this paper
• Pharmacological management of ocular hypertension: current approaches and future prospective.

  2013cites this paper
• Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues.

  2012cites this paper